Novavax Seeks FDA Approval For Its COVID Vaccine

Axios reports:

As one of America’s first big bets under Operation Warp Speed, Novavax’s COVID vaccine is notably late to the party as the Maryland biotech seeks a potential FDA emergency use authorization for its COVID shot.

But company leaders say they see a clear runway to market success for its protein-based product — not only as a booster for the vaccinated but as an alternative first-line defense for those who’ve refused mRNA shots.

Novavax’s vaccine uses a protein from the target virus combined with what’s called an adjuvant which enhances the body’s immune response. It can be stored in refrigerators instead of the ultra-cold storage needed by Moderna and Pfizer’s vaccines.

Read the full article.

The shot is already approved in Europe.

As one of America’s first big bets under Operation Warp Speed, Novavax’s COVID vaccine is notably late to the party. But company leaders say they see a clear runway to success. https://t.co/EZ9hA5jIse

— Axios (@axios) May 31, 2022